Novartis Archives -

Market Access/ News/ News/ News/ Sales and Marketing

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

Phil Taylor biosimilar, Byooviz, Cimerli, Coherus, Lucentis, Novartis, Roche, Samsung Bioepis 0 Comment

The US FDA has approved a new biosimilar of Roche and Novartis’ blockbuster ophthalmology therapy Lucentis – Coherus

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

https://pharmaphorum.com/news/pressure-rises-on-lucentis-as-coherus-biosimilar-gets-fda-nod/

News/ News/ Sales and Marketing

Novartis takes aim at MS blockbuster Tysabri in US and Europe

Phil Taylor Biogen, biosimilar, Novartis, Sandoz, Tysabri 0 Comment

Regulators in the US and Europe have started to review Novartis’ biosimilar version of Biogen’s big-selling multiple sclerosis

Novartis takes aim at MS blockbuster Tysabri in US and Europe

https://pharmaphorum.com/news/novartis-takes-aim-at-ms-blockbuster-tysabri-in-us-and-europe/

News/ News/ Sales and Marketing

Novartis faces tougher decision on Sandoz, as finances recover

Phil Taylor biosimilars, Financial, generics, M&A, Novartis, Sandoz 0 Comment

Novartis said this morning that it remains on course to make a decision on the future of its

Novartis faces tougher decision on Sandoz, as finances recover

https://pharmaphorum.com/news/novartis-faces-tougher-decision-on-sandoz-as-finances-recover/

Radiology technician examens mammography test

Market Access/ News/ News/ News/ Oncology

NICE backs two new breast cancer drugs for NHS use

Phil Taylor breast cancer, Gilead Sciences, HEOR, NHS, NICE, Novartis, Oncology, Piqray, Trodelvy 0 Comment

Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer

NICE backs two new breast cancer drugs for NHS use

https://pharmaphorum.com/news/nice-backs-two-new-breast-cancer-drugs-for-nhs-use/

News/ News/ News/ Oncology/ R&D

Novartis eyes earlier use of PD-1 drug in oesophageal cancer

Phil Taylor BeiGene, Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, Novartis, oesophageal cancer, Oncology, Opdivo, tislelizumab 0 Comment

Novartis is still waiting for FDA approval of its PD-1/PD-L1 inhibitor latecomer tislelizumab in relapsed oesophageal cancer, but

Novartis eyes earlier use of PD-1 drug in oesophageal cancer

https://pharmaphorum.com/oncology/novartis-eyes-earlier-use-of-pd-1-drug-in-oesophageal-cancer/

News/ News/ Sales and Marketing

Novartis will shed 7% of workforce in restructuring, say reports

Phil Taylor jobs, Novartis, Oncology, R&D, senior management, Vas Narasimhan 0 Comment

A Swiss newspaper has said Novartis’ previously announced restructuring programme could lead to 8,000 axed jobs, including up

Novartis will shed 7% of workforce in restructuring, say reports

https://pharmaphorum.com/news/novartis-will-shed-7-of-workforce-in-restructuring-say-reports/

Market Access/ News/ News/ News/ Patients

GSK pledges £1bn drive for infectious disease R&D

Phil Taylor developing countries, GlaxoSmithKline, HIV, infectious diseases, Malaria, Novartis, patients, tropical diseases, tuberculosis 0 Comment

GSK will invest around £1 billion ($1.2 billion) over a 10-year period to speed up R&D on infectious

GSK pledges £1bn drive for infectious disease R&D

https://pharmaphorum.com/news/gsk-pledges-1bn-drive-for-infectious-disease-rd/

News/ News/ News/ Oncology/ Sales and Marketing

Novartis bags FDA okay for BRAF-positive tumour combination

Phil Taylor BRAF, Mekinist, Novartis, novel targeted cancer treatments, Oncology, Tabrecta, Tafinlar 0 Comment

Novartis’ two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for

Novartis bags FDA okay for BRAF-positive tumour combination

https://pharmaphorum.com/news/novartis-bags-fda-okay-for-braf-positive-tumour-combination/

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

News/ News/ R&D

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

Phil Taylor beta thalassaemia, gene editing, Haematology, Novartis, partnering, Precision BioSciences, sickle cell disease 0 Comment

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

https://pharmaphorum.com/news/precision-bio-climbs-on-near-1-5bn-sickle-cell-pact-with-novartis/

Trending

Novartis

Login